Anti-MRSA cephalosporins Bristol-Myers Squibb.
BMS is investigating a series of cephalosporins for potential use in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection [274213]. In vitro activity tests resulted in a minimum inhibitory concentration (MIC) of 1 to 8 microg/ml against MRSA 1274213]. A series of C(3) benzoyloxymethyl cephalosporins exhibited in vitro activity against MRSA and methicillin-susceptible Staphylococcus aureus (MSSA), with MIC values ranging from 0.007 to 2 microM, and improved in vivo stability in human plasma [258890].
Johnson
A P
AP
Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, London, UK. ajohnson@phls.nhs.uk
D000818:Animals; D001419:Bacteria / Q000187:drug effects*; D002511:Cephalosporins / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity; D006801:Humans; D016106:Methicillin Resistance; D051379:Mice; D009025:Morpholines / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology*; D013329:Structure-Activity Relationship
D002511:Cephalosporins; D009025:Morpholines; D011725:Pyridines; C452864:BMS-247243